Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

153 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Estimation of the determinants for HIV late presentation using the traditional definition and molecular clock-inferred dates: Evidence that older age, heterosexual risk group and more recent diagnosis are prognostic factors.
Kostaki EG, Limnaios S, Adamis G, Xylomenos G, Chini M, Mangafas N, Lazanas M, Patrinos S, Metallidis S, Tsachouridou O, Papastamopoulos V, Chatzidimitriou D, Antoniadou A, Papadopoulos A, Protopapas K, Tsiara C, Psichogiou M, Basoulis D, Pilalas D, Paraskeva D, Chrysos G, Paparizos V, Kourkounti S, Sambatakou H, Bolanos V, Sipsas NV, Lada M, Barbounakis E, Kantzilaki E, Panagopoulos P, Petrakis V, Drimis S, Katsarolis I, Lagiou P, Hatzakis A, Magiorkinis G, Skoura L, Paraskevis D. Kostaki EG, et al. Among authors: sambatakou h. HIV Med. 2022 Dec;23(11):1143-1152. doi: 10.1111/hiv.13415. Epub 2022 Oct 18. HIV Med. 2022. PMID: 36258653 Free PMC article.
Virological and immunological response to HAART therapy in a community-based cohort of HIV-1-positive individuals.
Touloumi G, Paparizos V, Sambatakou H, Katsarou O, Chrysos G, Kordossis T, Antoniadou A, Hatzitheodorou H, Stavrianeas N, Gargalianos P, Karafoulidou A, Lazanas M, Giamarelou H, Hatzakis A. Touloumi G, et al. Among authors: sambatakou h. HIV Clin Trials. 2001 Jan-Feb;2(1):6-16. doi: 10.1310/YN11-XJ4L-9YHF-19E4. HIV Clin Trials. 2001. PMID: 11590509 Clinical Trial.
Low-dose IFN-alpha monotherapy in treatment-naive individuals with HIV-1 infection: evidence of potent suppression of viral replication.
Hatzakis A, Gargalianos P, Kiosses V, Lazanas M, Sypsa V, Anastassopoulou C, Vigklis V, Sambatakou H, Botsi C, Paraskevis D, Stalgis C. Hatzakis A, et al. Among authors: sambatakou h. J Interferon Cytokine Res. 2001 Oct;21(10):861-9. doi: 10.1089/107999001753238114. J Interferon Cytokine Res. 2001. PMID: 11710999 Clinical Trial.
Increasing prevalence of HIV-1 subtype A in Greece: estimating epidemic history and origin.
Paraskevis D, Magiorkinis E, Magiorkinis G, Sypsa V, Paparizos V, Lazanas M, Gargalianos P, Antoniadou A, Panos G, Chrysos G, Sambatakou H, Karafoulidou A, Skoutelis A, Kordossis T, Koratzanis G, Theodoridou M, Daikos GL, Nikolopoulos G, Pybus OG, Hatzakis A; Multicentre Study on HIV Heterogeneity. Paraskevis D, et al. Among authors: sambatakou h. J Infect Dis. 2007 Oct 15;196(8):1167-76. doi: 10.1086/521677. Epub 2007 Sep 13. J Infect Dis. 2007. PMID: 17955435
Effects of first antiretroviral regimen on lipid levels in HIV (+) individuals.
Papadopoulos A, Pantazis N, Panagopoulos P, Kourkounti S, Xylomenos G, Chini M, Petrikkos G, Sambatakou H, Ioannidou P, Kordosis T, Panos G, Touloumi G. Papadopoulos A, et al. Among authors: sambatakou h. J Chemother. 2012 Feb;24(1):38-47. doi: 10.1179/1120009X12Z.0000000008. J Chemother. 2012. PMID: 22546723
Effect of HIV type 1 subtype on virological and immunological response to combination antiretroviral therapy: evidence for a more rapid viral suppression for subtype A than subtype B-infected Greek individuals.
Paraskevis D, Touloumi G, Bakoyannis G, Paparizos V, Lazanas M, Gargalianos P, Chryssos G, Antoniadou A, Psichogiou M, Panos G, Katsarou O, Sambatakou H, Kordossis T, Hatzakis A; AMACS. Paraskevis D, et al. Among authors: sambatakou h. AIDS Res Hum Retroviruses. 2013 Mar;29(3):461-9. doi: 10.1089/AID.2012.0143. Epub 2012 Nov 6. AIDS Res Hum Retroviruses. 2013. PMID: 23034083
Patterns of drug resistance among newly diagnosed HIV-1 infected patients in Greece during the last decade: the crucial role of transmission networks.
Paraskevis D, Zavitsanou A, Magiorkinis E, Gargalianos P, Xylomenos G, Lazanas M, Chini M, Skoutelis A, Papastamopoulos V, Antoniadou A, Papadopoulos A, Psichogiou M, Daikos G, Vassilakis A, Chrysos G, Paparizos V, Kourkounti S, Sambatakou H, Kordossis T, Koratzanis G, Panagopoulos P, Maltezos E, Drimis S, Hatzakis A. Paraskevis D, et al. Among authors: sambatakou h. J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19742. doi: 10.7448/IAS.17.4.19742. eCollection 2014. J Int AIDS Soc. 2014. PMID: 25397487 Free PMC article.
Boosted lopinavir- versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: a prospective study of HIV-infected individuals in high-income countries.
HIV-CAUSAL Collaboration; Cain LE, Phillips A, Olson A, Sabin C, Jose S, Justice A, Tate J, Logan R, Robins JM, Sterne JA, van Sighem A, Reiss P, Young J, Fehr J, Touloumi G, Paparizos V, Esteve A, Casabona J, Monge S, Moreno S, Seng R, Meyer L, Pérez-Hoyos S, Muga R, Dabis F, Vandenhende MA, Abgrall S, Costagliola D, Hernán MA. HIV-CAUSAL Collaboration, et al. Clin Infect Dis. 2015 Apr 15;60(8):1262-8. doi: 10.1093/cid/ciu1167. Epub 2015 Jan 6. Clin Infect Dis. 2015. PMID: 25567330 Free PMC article.
Why START? Reflections that led to the conduct of this large long-term strategic HIV trial.
INSIGHT Strategic Timing of AntiRetroviral Treatment (START) Study Group; Lundgren J, Babiker A, Gordin F, Emery S, Fätkenheuer G, Molina JM, Wood R, Neaton JD. INSIGHT Strategic Timing of AntiRetroviral Treatment (START) Study Group, et al. HIV Med. 2015 Apr;16 Suppl 1(0 1):1-9. doi: 10.1111/hiv.12227. HIV Med. 2015. PMID: 25711317 Free PMC article. No abstract available.
153 results